Core Viewpoint - The stock of药捷安康-B (02617) experienced a significant decline of over 11% during trading, with a current drop of 9.74% to HKD 176.2, and a trading volume of HKD 591 million. The company announced plans to convert 44.9711 million domestic shares held by 10 shareholders into H-shares, representing approximately 11.33% of the total issued shares, pending regulatory approvals [1][1][1]. Group 1 - The company’s stock price fell sharply after a recent surge, indicating volatility in investor sentiment [1][1]. - The recent rebound from October 16 to 17 saw a cumulative increase of nearly 80%, driven by international short-term speculative funds [1][1]. - The rebound was characterized as a "window for unloading" by domestic major funds, suggesting that the primary holders were selling rather than buying [1][1]. Group 2 - The analysis from智通财经APP highlighted that the recent price surge was not supported by the main holding group, which instead became the largest sellers [1][1]. - The sustainability of the rebound is questioned, as it relies heavily on subsequent market participation and inflow of speculative funds [1][1].

Core Viewpoint - The stock of药捷安康-B (02617) experienced a significant decline of over 11% during trading, closing down 9.74% at HKD 176.2, with a trading volume of HKD 591 million [1] Group 1: Company Announcement - The company announced that its board has approved the application to convert 44.9711 million domestic shares held by 10 shareholders into H-shares, which represents approximately 11.33% of the total issued shares [1] - Upon obtaining all necessary approvals and complying with applicable laws and regulations, these domestic shares will be converted into H-shares and will qualify for listing and trading on the main board of the Hong Kong Stock Exchange [1] Group 2: Market Reaction - Notably, on October 16-17, the stock rebounded strongly, with a cumulative increase of nearly 80% over two days [1] - The recent violent rebound was characterized as being driven by international short-term speculative funds, while domestic institutional investors utilized this as an "exit window" [1] - When the largest holding group not only refrains from buying but instead becomes the largest seller, the foundation of this rebound is considered to be hollow, relying entirely on subsequent follow-up buying and short-term international funds [1]

Core Viewpoint - On October 20, China Life made its first appearance on the Hong Kong Stock Connect active trading list in nearly a month, with a trading volume of 10.41 billion HKD and a net buying amount of 1.37 billion HKD, closing up 2.44% [1] Trading Activity Summary - The total trading volume of active stocks on the Hong Kong Stock Connect on October 20 was 369.37 billion HKD, accounting for 33.62% of the day's total trading amount, with a net selling amount of 21.97 billion HKD [1] - Alibaba-W led the trading volume with 96.98 billion HKD, followed by SMIC and Tencent Holdings with trading amounts of 53.97 billion HKD and 44.91 billion HKD, respectively [1] Frequent Trading Stocks - The stocks that appeared most frequently on the active trading list over the past month were Alibaba-W and Huahong Semiconductor, each appearing 15 times, indicating strong interest from Hong Kong Stock Connect funds [1] - China Life's recent appearance marks its first in nearly a month, highlighting a potential shift in investor interest [1] Individual Stock Performance - Tencent Holdings had a trading amount of 44.91 billion HKD with a net buying amount of 0.97 billion HKD, closing up 3.21% [1] - SMIC recorded a trading amount of 53.97 billion HKD with a net selling amount of 3.25 billion HKD, closing up 3.91% [1] - Alibaba-W had a significant trading amount of 96.98 billion HKD but faced a net selling amount of 17.54 billion HKD, closing up 4.86% [1] - China Life's trading amount was 10.41 billion HKD with a net buying amount of 1.37 billion HKD, closing at 23.520 HKD, up 2.44% [1]

| 代码 | 简称 | 类型 | 成交金额（万港元） | 成交净买入（万港元） | 日涨跌幅（%） | | --- | --- | --- | --- | --- | --- | | 09988 | 阿里巴巴-W | 港股通(沪) | 578712.83 | -120489.75 | 4.86 | | 09988 | 阿里巴巴-W | 港股通(深) | 391085.00 | -54894.03 | 4.86 | | 00981 | 中芯国际 | 港股通(沪) | 323132.21 | -51384.43 | 3.91 | | 00700 | 腾讯控股 | 港股通(沪) | 293306.14 | -16171.79 | 3.21 | | 01810 | 小米集团-W | 港股通(沪) | 216834.31 | -39191.46 | 2.57 | | 00981 | 中芯国际 | 港股通(深) | 216571.00 | 18934.78 | 3.91 | | 01347 | 华虹半导体 | 港股通(沪) | 171075.45 | 10500.99 | 2.77 | | 00883 | 中国海洋石油 ...

Company News - China Mobile (00941.HK) reported a total operating revenue of 794.7 billion yuan for the first three quarters, a year-on-year increase of 0.4%, with a net profit of 115.4 billion yuan, up 4% [1] - As of September 30, communication service revenue was 683.1 billion yuan, a 0.8% increase year-on-year, while sales of products and others were 111.5 billion yuan, a decrease of 1.7% [1] - Mobile internet traffic increased by 8.3% year-on-year, with a mobile ARPU of 48.0 yuan [1] - Contemporary Amperex Technology Co., Ltd. (宁德时代) (03750.HK) achieved revenue of approximately 283.07 billion yuan from January to September, a year-on-year increase of 9.28%, with a net profit of approximately 49.03 billion yuan, up 36.2% [1] Financing and Buyback Dynamics - HSBC Holdings (00005.HK) repurchased 4.64 billion HKD worth of shares, totaling 4.5664 million shares, at prices ranging from 100.6 to 102.4 HKD [6] - Mengniu Dairy (02319.HK) repurchased shares worth 10.14 million HKD, totaling 700,000 shares, at prices between 14.37 and 14.52 HKD [6] - Lianyi Technology (09959.HK) repurchased shares worth 743.93 million HKD, totaling 2.45 million shares, at prices ranging from 2.97 to 3.07 HKD [7]

药捷安康-B(02617)发布公告，于2025年10月20日，公司董事会已考虑及批准向中国证监会提交申请， 将公司10名股东持有的4497.11万股公司内资股转换为公司H股，占公司于本公告日期已发行股份总数约 11.33%。于取得所有相关批准(包括中国证监会及联交所的批准)并遵守所有适用法律、法规及规则后， 该等内资股将转换为H股，并符合资格于联交所主板上市及买卖。 ...

智通财经APP讯，药捷安康-B(02617)发布公告，于2025年10月20日，公司董事会已考虑及批准向中国证 监会提交申请，将公司10名股东持有的4497.11万股公司内资股转换为公司H股，占公司于本公告日期已 发行股份总数约11.33%。于取得所有相关批准(包括中国证监会及联交所的批准)并遵守所有适用法律、 法规及规则后，该等内资股将转换为H股，并符合资格于联交所主板上市及买卖。 ...

Core Viewpoint - The company,药捷安康-B (02617.HK), announced its plan to convert 44.9711 million domestic shares held by 10 shareholders into H-shares, which represents approximately 11.33% of the total shares issued as of the announcement date [1] Group 1 - The board of directors has approved the application to the China Securities Regulatory Commission for the conversion of domestic shares into H-shares [1] - The conversion and listing will occur after obtaining all necessary approvals from the China Securities Regulatory Commission and the Stock Exchange of Hong Kong, and complying with all applicable laws and regulations [1] - According to the company's articles of association, there is no need to hold a shareholders' meeting to approve the conversion and listing [1]

TransThera Sciences (Nanjing), Inc. 藥捷安康（南京）科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 （股份代號：2617） 內幕消息公告 本公司建議實行H股全流通 本公告由藥捷安康（南京）科技股份有限公司（「本公司」）根據香港聯合交易所有限 公司證券上市規則（「上市規則」）第13.09(2)(a)條及證券及期貨條例（香港法例第 571章）第XIVA部之內幕消息條文（定義見上市規則）作出。 茲提述中國證券監督管理委員會（「中國證監會」）於2019年11月14日頒佈並於 2023年8月10日進一步修訂之《H股公司境內未上市股份申請「全流通」業務指引》 （「指引」），內容有關H股於香港聯合交易所有限公司（「聯交所」）上市之公司申請 境內未上市股份（定義見指引）在聯交所流通之程序。 鑒於指引，於2025年10月20日，本公司董事（「董事」）會（「董事會」）已考慮 ...

每经AI快讯，10月20日，截至发稿，永泰生物-B(06978.HK)涨14.94%、和珀医药-B(02142.HK)涨 5.32%、荣昌生物(09995.HK)涨5.14%、药捷安康(02617.HK)涨5.02%、基石药业-B(02616.HK)涨3.92%。 ...